Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Investor Presentation (August 2020)
22 slides from Proteomics International Laboratories's investor presentation, Aug 26, 2020
Slide 1: Investor Presentation: Building a Global Diagnostics Business
Investor Presentation 26th August 2020 BUILDING A GLOBAL ASX: PIQ DIAGNOSTICS BUSINESS
Slide 2: Disclaimer
DISCLAIMER ASX:PIQ This Presentation is provided by Proteomics International Laboratories Ltd (PILL, the Company). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in deciding whether or not to seek to purchase
Slide 3: Corporate Overview
CORPORATE OVERVIEW ASX:PIQ Proteomics International Laboratories Ltd (ASX: PIQ) is a medical CORPORATE SNAPSHOT – 25/8/2020 technology company at the forefront of predictive diagnostics ASX code PIQ and bioanalytical services Share Price $0.605 Shares on issue (+ 4m options) 92m DIAGNOSTICS Market C
Slide 4: Promarker – Platform Technology
PROMARKER – PLATFORM TECHNOLOGY ASX:PIQ PromarkerTM is a platform technology that can identify unique protein biomarkers ‘fingerprints’ The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics to formulate commercial diagnostic tests 4
Slide 5: PromarkerD: Predictive Test for Diabetic Kidney Disease
PromarkerD ASX:PIQ PREDICTIVE TEST FOR DIABETIC KIDNEY DISEASE 5
Slide 6: Building a Global Diagnostics Business
BUILDING A GLOBAL DIAGNOSTICS BUSINESS ASX:PIQ PromarkerD is revenue ready and Proteomics International is currently in discussions globally to bring the test to market Simple Technology Platform Certified laboratories can easily introduce the PromarkerD ✓ PromarkerD Immunoassay ready immunoassay as
Slide 7: Market Size?
MARKET SIZE? 50% UNDIAGNOSED Nth America & Caribbean ASX:PIQ Europe South & Central America South-East Asia Middle East ➢ Global IVD market worth & North Africa Western Pacific US$67 billion in 2019, Africa projected to reach $91 billion by 2027 Sth/Ctrl America ➢ Proteomics market valued at US$24 b
Slide 8: A Major Opportunity
A MAJOR OPPORTUNITY ASX:PIQ THE PROBLEM 463 million people have diabetes 1 in 3 diabetic adults currently have chronic kidney disease There are no early symptoms of diabetic kidney disease - Kidney function can fall below 15-20% with no symptoms The current standard-of-care tests cannot predict the
Slide 9: PromarkerD Platforms
PromarkerD PLATFORMS ASX:PIQ PREDICTIVE TEST for DIABETIC KIDNEY DISEASE PromarkerD assay can be readily ported to different pathology lab platforms Immunoassay Kit Laboratory Developed Test - LDT Automated Immunoassay ▪ Cost-effective, easy-to-use technology platforms ▪ Regulatory approval – Europe
Slide 10: PromarkerD in the Clinic
PromarkerD IN THE CLINIC ASX:PIQ PREDICTIVE TEST for DIABETIC KIDNEY DISEASE PromarkerD patient reports use a traffic light scoring system for optimal performance A simple blood test that measures three plasma proteins combined with three clinical factors (age, cholesterol, eGFR) In published clinic
Slide 11: Treatments for DKD - SGLT2 Inhibitors
TREATMENTS FOR DKD - SGLT2 INHIBITORS ASX:PIQ The GLIFLOZINS COMMERCIAL UPSIDE ▪ SGLT2 inhibitors, known as Gliflozins, treat diabetes ▪ PromarkerD could become a prognostic test for big by helping the kidneys to lower blood glucose levels pharma companies that are: ▪ Empagliflozin (Lilly & Boehring
Slide 12: Janssen Collaboration
JANSSEN COLLABORATION ASX:PIQ Proteomics International and Janssen are studying the performance of PromarkerD in predicting decline in kidney function and treatment response in patients from a Janssen completed clinical trial STAGE 1 STUDY COLLABORATION EXPANDED TO STAGE 2 PromarkerD validated in gl
Slide 13: Route to Market
ROUTE TO MARKET ASX:PIQ LABORATORY DEVELOPED TEST (LDT) IN VITRO DIAGNOSTIC TEST (IVD) ▪ Immunoassay or Mass spectrometry ▪ Immunoassay kit or automated machine platform ▪ Tests run via certified laboratories - both platforms standard to pathology laboratories ▪ The LDT permits fast ▪ Assay validate
Slide 14: Market Opportunity – PromarkerD
MARKET OPPORTUNITY – PromarkerD ASX:PIQ Market assumptions: ➢ Test is performed once per year per patient on average [Standard of care: High- risk patients are tested every 3-6 months; Low-risk every 2 years]. ➢ Test price of US$55-$150 [$55 is based on use of existing CPT codes for similar analytes
Slide 15: Diagnostics Pipeline
FURTHER GLOBAL POTENTIAL IN NEW MARKETS Proteomics endeavours to leverage its PromarkerTM Platform to develop and commercialise a suite of diagnostic tests DIAGNOSTICS Potential for faster market adoption for a new diagnostic test, PIPELINE post a successful PromarkerD commercialisation Enormous mar
Slide 16: Endometriosis
ENDOMETRIOSIS ASX:PIQ WHAT IS ENDOMETRIOSIS? A debilitating condition in which tissue that normally lines the uterus grows outside the uterus (on the ovaries, fallopian tubes or the intestines) The most common symptoms are chronic pain and menstrual irregularities Diagnosis typically takes 7 to 12 y
Slide 17: COVID-19 Diagnostics & Oxidative Stress
COVID-19 DIAGNOSTICS & OXIDATIVE STRESS COVID-19 DIAGNOSTICS OXIDATIVE STRESS (2-TAG) ▪ Develop a rapid diagnostic test for the identification ▪ The patented technology called "2-tag" measures of the SARS-CoV-2 virus the oxidative stress in a system (i.e. body of human or animal) ▪ Half of people te
Slide 18: Analytical Services
ANALYTICAL SERVICES Proteomics International state-of-the-art biomarker analysis facilities ▪ World leading facility in Western Australia – Public Private Partnership co-investing >$4m including from Federal and State Government agencies ▪ Best in class Quality Control testing ▪ Biosimilars & biolog
Slide 19: Milestones & Upcoming Catalysts
MILESTONES & UPCOMING CATALYSTS EXCEPTIONAL GLOBAL OPPORTUNITY SHARE PRICE CATALYSTS 2020-21 PromarkerD ✓ Proven diagnostics business with global potential ➢ Results from Janssen studies – Stage 2 ✓ Scalable licensing model with high margins and low rollout cost - diagnostic capability to assist dru
Slide 20: Appendices - Peer Comparison
APPENDICES - PEER COMPARISON Addressable Market Share FY19 FY19 Net Stock Code Company Focus Market(s) Capitalisation Price Revenue Profit/Loss US$Bn DKD test based on AI and a combination of predictive blood-based biomarkers, £407m + RENX.LSE 565p & £6.9m genetic factors and electronic health US$81
Slide 21: Board & Management
BOARD & Terry Sweet FAICD, Chairman Director of several listed companies over the past 30 years in both executive and MANAGEMENT non-executive capacities. Companies include XRFAfrica Scientific Ltd, where Managing Director for 4 years, Western Biotechnology Ltd, Heartlink ASX:PIQ South & he was Ltd,
Slide 22: Contact
CONTACT ASX:PIQ Richard Lipscombe Dirk van Dissel Managing Director Corporate Advisor & Investor Relations T: +61 8 9389 1992 Candour Advisory E: r.lipscombe@proteomicsinternational.com T: +61 408 326 367 www.proteomicsinternational.com E: dirk@candouradvisory.com.au ASX:PIQ
Proteomics International Laboratories — Investor Presentation (August 2020) on 6ix